Posoleucel is under clinical development by AlloVir and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Posoleucel’s likelihood of approval (LoA) and phase transition for Hemorrhagic Cystitis (Haemorrhagic Cystitis) took place on 05 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Posoleucel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Posoleucel (ALVR-105) is under development for the prophylaxis and treatment of hematopoietic stem cell transplant-associated viral infections such as refractory cytomegalovirus infection (CMV), adenovirus infection, Epstein–Barr virus infection, human herpesvirus 6 infection, hemorrhagic cystitis, BK virus infection, polyomavirus Infections (JC virus), and multi-virus infections. The drug candidate is an allogeneic, off-the-shelf multi-virus specific T-cell therapy, administered through intravenous injection and infusion. It was also under development for the prophylaxis and treatment of solid organ transplant (SOT) associated infections such as nephritis (BK-nephritis) and viral infections associated with primary immunodeficiency disorder.
AlloVir, formerly ViraCyte, develops and delivers novel cell therapies to restore natural T-cell immunity for the treatment of patients suffering from life-threatening virus-associated diseases. The company is a global leader in the development of VST immunotherapies. The company lead pipeline candidate is Viralym-M (ALVR105) targeting Cytomegalovirus (CMV), Adenovirus (AdV), BK Virus (BKV), Human Herpesvirus-6 (HHV-6) and Epstein-Barr (EBV). Other pipeline candidates include ALVR106 for the treatment of Influenza, Parainfluenza Virus (PIV), Respiratory syncytial virus (RSV), and Human Metapneumovirus (hMPV); ALVR109 for COVID-19; ALVR107 for Hepatitis B; and ALVR108 for Human Herpesvirus-8 (HHV-8). The company is headquartered in Cambridge, Massachusetts, the US.
Quick View Posoleucel LOA Data
|Highest Development Stage|